ARTICLE | Clinical News
BASF starts Phase III
February 4, 2000 8:00 AM UTC
BASF Pharma (Ludwigshafen, Germany) began Phase III trials of D2E7, a human anti-TNF monoclonal antibody to treat rheumatoid arthritis. The compound is licensed from Cambridge Antibody Technology (LSE...